Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00668642
• Other study ID #: EH07-109
• Status: Completed
• Phase: Phase 2
• Start date: March 2007
• Est. completion date: May 2013

Study information

• Verified date: July 2023
• Source: NorthShore University HealthSystem
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Description:

We have shown in a murine model of treatment with intermittent androgen ablation therapy of prostate cancer that when dutasteride is given during the regrowth phase (off-phase) of intermittent therapy, that tumor growth is inhibited and that survival is improved. We have also shown that testosterone is a more potent inducer of certain tumor suppressor androgen response genes than dihydrotestosterone. In this murine model, we showed that use of a 5-alpha reductase inhibitor (dutasteride) resulted in significant hyperinduction of the U19 tumor suppressor androgen response gene during the regrowth phase of treatment. In the current clinical trial, we will determine if use of dutasteride in men with advanced prostate cancer during the off-phase of intermittent androgen ablation therapy will also result in hyperinduction of these tumor suppressor androgen response genes. Gene expression will be measured in tumor tissue obtained by prostate biopsies during the off-phase when the testosterone level has normalized. Prostate-specific antigen (PSA) levels will also be measured to determine the PSA doubling time during the off-phase to determine the effect of dutasteride on PSA kinetics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven prostate cancer

• Patients are hormone-naive

• Patients either to begin androgen ablation therapy with luteinizing hormone-releasing hormone (LHRH) agonist or already receiving therapy with LHRH agonist

• Advanced prostate cancer with either positive pelvic nodes or bone/visceral metastasis

• Must have an intact prostate (no previous surgery or XRT)

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Recovery from any major infection or surgical procedure

• Signed informed consent

Exclusion Criteria:

• Known intolerance or allergy to dutasteride

• Concomitant chemotherapy, biologic therapy, or XRT to prostate

• Bilateral orchiectomy

• Prior malignancy within 5 years of registration

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Dutasteride
0.5 mg capsule given orally on daily basis
• Placebo
Identical placebo

Locations

Country	Name	City	State
United States	Northwestern University Medical Center	Chicago	Illinois
United States	University of Chicago Hospitals and Clinics	Chicago	Illinois
United States	NorthShore University HealthSystem	Evanston	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
NorthShore University HealthSystem	Northwestern University, University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative Expression of U19 Gene in Tumor From Prostate Gland During First Off-cycle.	Calculation of the level of gene expression of the U19 tumor suppressor gene compared between the 2 arms at the end of "off-treatment" cycle 1.	At the end of off-cycle 1 defined by when the testosterone level reaches normal (approximately 6 months)
Secondary	Determination of Prostate-specific Antigen (PSA) Doubling Time During First Off-cycle	Calculation of number of months when baseline PSA doubles compared between the 2 arms at the end of "off-treatment" cycle 1.	At month 9 and ongoing monthly until end of off-cycle 1 defined by when the testosterone level reaches normal (approximately 6 months)